[go: up one dir, main page]

WO2002056941A3 - Methode de traitement de l'acrosyndrome - Google Patents

Methode de traitement de l'acrosyndrome Download PDF

Info

Publication number
WO2002056941A3
WO2002056941A3 PCT/US2002/003852 US0203852W WO02056941A3 WO 2002056941 A3 WO2002056941 A3 WO 2002056941A3 US 0203852 W US0203852 W US 0203852W WO 02056941 A3 WO02056941 A3 WO 02056941A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
vascular disease
peripheral vascular
mammal
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/003852
Other languages
English (en)
Other versions
WO2002056941A2 (fr
Inventor
Theodore M Danoff
Jeffrey Granett
Diane K Jorkasky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to AU2002250044A priority Critical patent/AU2002250044A1/en
Publication of WO2002056941A2 publication Critical patent/WO2002056941A2/fr
Publication of WO2002056941A3 publication Critical patent/WO2002056941A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une méthode de prévention ou de réduction du dysfonctionnement de l'accès vasculaire associée à l'insertion ou réparation d'un shunt, d'une fistule ou d'un cathéter à demeure dans une veine, chez un mammifère, de préférence un être humain, ou sur une méthode de traitement de l'acrosyndrome chez un mammifère, notamment un être humain souffrant de cette pathologie, consistant à administrer au patient un acide N-(3', 4'-diméthoxycinnamoyl)anthranilique ou son sel pharmaceutiquement acceptable selon un dosage compris entre 0,1 mg et environ 2 400 mg.
PCT/US2002/003852 2001-01-19 2002-01-17 Methode de traitement de l'acrosyndrome Ceased WO2002056941A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002250044A AU2002250044A1 (en) 2001-01-19 2002-01-17 Method for the treatment of peripheral vascular disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26286101P 2001-01-19 2001-01-19
US60/262,861 2001-01-19
US26829301P 2001-02-13 2001-02-13
US60/268,293 2001-02-13
US26898601P 2001-02-15 2001-02-15
US60/268,986 2001-02-15

Publications (2)

Publication Number Publication Date
WO2002056941A2 WO2002056941A2 (fr) 2002-07-25
WO2002056941A3 true WO2002056941A3 (fr) 2003-03-27

Family

ID=27401546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003852 Ceased WO2002056941A2 (fr) 2001-01-19 2002-01-17 Methode de traitement de l'acrosyndrome

Country Status (2)

Country Link
AU (1) AU2002250044A1 (fr)
WO (1) WO2002056941A2 (fr)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ATHEROSCLEROSIS, vol. 118, no. 2, December 1995 (1995-12-01), pages 213 - 221 *
CIRCULATION, vol. 99, no. 7, 23 February 1999 (1999-02-23), pages 919 - 924 *
DATABASE MEDLINE [online] (COLUMBUS, OH, USA); CAPPER, E.A. ET AL.: "Modulation of human monocyte activities by tranilast, ST 252218, a compound demonstrating efficacy in restenosis", XP002953930, accession no. STN Database accession no. 2001056667 *
DATABASE MEDLINE [online] (COLUMBUS, OH, USA); MATSUMURA, T. ET AL.: "Suppression of atherosclerotic development in watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast", XP002953929, accession no. STN Database accession no. 1999152078 *
DATABASE MEDLINE [online] (COLUMBUS, OH, USA); MIYAZAWA, K. ET AL.: "Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats", XP002953931, accession no. STN Database accession no. 96366138 *
J. PHARMACOL. EXPER. THER., vol. 295, no. 3, December 2000 (2000-12-01), pages 1061 - 1069 *

Also Published As

Publication number Publication date
AU2002250044A1 (en) 2002-07-30
WO2002056941A2 (fr) 2002-07-25

Similar Documents

Publication Publication Date Title
WO2004028570A3 (fr) Methode de traitement de l'acouphene severe
WO2002100390A3 (fr) Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain
WO2003072024A3 (fr) Procedes concernant le traitement d'une affection vasculaire
WO2004110502A3 (fr) Stent endoluminal helicoidal et procedes connexes
WO2005063745A3 (fr) Nouveaux composes de spiroindoline ou de spiroisoquinoline, methodes d'utilisation et compositions associees
CA2427227A1 (fr) Compose de lactam
EP1089738A4 (fr) Verrous antimicrobiens comprenant des derives de la taurinamide et d'acides carboxyliques et/ou leurs sels
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
WO2002056912A3 (fr) Methode de traitement du cancer
CA2594215A1 (fr) Compositions a nanoparticules a liberation prolongee et procedes d'utilisation
WO2003072040A3 (fr) Administration d'agents pour le traitement d'une inflammation
AU6158001A (en) Drug/drug delivery systems for the prevention and treatment of vascular disease
WO2006033006A3 (fr) Combinaisons therapeutiques comprenant un inhibiteur des polymerases poly(adp-ribose)
WO2004043341A3 (fr) Traitement pour choc hémorragique
WO2002000210A3 (fr) Traitement de maladie cardio-vasculaire
WO2001068125A3 (fr) Methodes et compositions de traitement et de prevention de la dyserection
EP0838225A3 (fr) Solution locale anesthétique aqueuse
WO2002102743A3 (fr) Aminoalkylesters d'acide diphenylalcoxy-acetique n et alpha-substitues deuterises et medicaments contenant lesdits composes
WO2001089494A3 (fr) Procede d'administration d'un bisphosphonate
WO2001030331A3 (fr) Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c
TW200616644A (en) Medicine for prevention or treatment of diabetes
CA2344910A1 (fr) Methode et composition pharmaceutique pour le traitement des maladies renales
EP0799618A3 (fr) Utilisation d'antagonistes de l'adrénorécepteur alpha 1 dans la fabrication d'unmédicament pur la prévention et au traitment du cancer
WO2004069254A3 (fr) Utilisation du dipyridamole ou mopidamole pour le traitement et la prevention de troubles dependant de mmp-9
WO2002056941A3 (fr) Methode de traitement de l'acrosyndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP